Evaluation of GLP-1 drug effects on obstetric and perinatal outcomes provides critical safety data for the growing number of pregnancies exposed to these drugs.
Key findingEvaluation of GLP-1 drug effects on obstetric and perinatal outcomes provides critical safety data f
What the researchers found
Evaluation of GLP-1 drug effects on obstetric and perinatal outcomes provides critical safety data for the growing number of pregnancies exposed to these drugs.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Studies published 2020-2025 searched across PubMed, Embase, and Cochrane Central. Included RCTs and cohorts with control groups.
How the study worked
In publication.
Who was studied
Women exposed to GLP-1 receptor agonists during pregnancy or preconception
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis.
Journal of gynecology obstetrics and human reproduction, 54(10), 103046
Citation
Armstrong, Bruna Benigna Sales; Servidoni, Ana Clara Pimenta; Martin, Giovanna Cristina de Castro; Machado, Guilherme Franceschini; Amador, Wellgner Fernandes Oliveira; Yousif, Abdelrahman. (2025). Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis.. Journal of gynecology obstetrics and human reproduction, 54(10), 103046. https://doi.org/10.1016/j.jogoh.2025.103046